DexCom, Inc. $DXCM Position Lifted by Intech Investment Management LLC

Intech Investment Management LLC grew its holdings in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 376.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 117,774 shares of the medical device company’s stock after acquiring an additional 93,040 shares during the period. Intech Investment Management LLC’s holdings in DexCom were worth $10,163,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also recently modified their holdings of the company. Geneva Capital Management LLC raised its stake in shares of DexCom by 14.3% in the third quarter. Geneva Capital Management LLC now owns 149,856 shares of the medical device company’s stock worth $12,931,000 after buying an additional 18,773 shares during the period. Phoenix Financial Ltd. lifted its position in shares of DexCom by 7.6% during the 3rd quarter. Phoenix Financial Ltd. now owns 5,015 shares of the medical device company’s stock valued at $433,000 after buying an additional 355 shares in the last quarter. Danske Bank A S grew its stake in shares of DexCom by 59.5% during the 3rd quarter. Danske Bank A S now owns 311,007 shares of the medical device company’s stock valued at $26,837,000 after acquiring an additional 115,958 shares during the period. Diversified Trust Co grew its stake in shares of DexCom by 13.1% during the 3rd quarter. Diversified Trust Co now owns 11,264 shares of the medical device company’s stock valued at $972,000 after acquiring an additional 1,302 shares during the period. Finally, William Blair Investment Management LLC grew its stake in shares of DexCom by 1.8% during the 3rd quarter. William Blair Investment Management LLC now owns 176,575 shares of the medical device company’s stock valued at $15,237,000 after acquiring an additional 3,122 shares during the period. Institutional investors own 97.75% of the company’s stock.

DexCom Price Performance

Shares of DexCom stock opened at $81.61 on Tuesday. The company has a market capitalization of $30.44 billion, a price-to-earnings ratio of 32.00, a PEG ratio of 1.34 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.74 and a debt-to-equity ratio of 0.49. The stock’s 50-day simple moving average is $84.17 and its 200-day simple moving average is $75.25. DexCom, Inc. has a 52 week low of $56.72 and a 52 week high of $92.59.

DexCom (NASDAQ:DXCM – Get Free Report) last released its earnings results on Thursday, October 29th. The medical device company reported $0.73 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.05. The firm had revenue of $1.34 billion during the quarter, compared to analysts’ expectations of $1.33 billion. DexCom had a return on equity of 37.77% and a net margin of 19.42%. The firm’s revenue was up 11.1% on a year-over-year basis. During the same quarter last year, the business posted $0.61 earnings per share. As a group, analysts expect that DexCom, Inc. will post 2.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Argus increased their target price on shares of DexCom from $86.00 to $96.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Wells Fargo & Company lifted their price target on shares of DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a report on Friday, July 31st. TD Cowen reiterated a “buy” rating and issued a $95.00 price target on shares of DexCom in a research report on Friday, September 18th. Deutsche Bank upped their price target on shares of DexCom from $86.00 to $92.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Finally, Weiss Ratings raised shares of DexCom from a “hold (c)” rating to a “hold (c+)” rating in a research note on Tuesday, October 6th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-four have given a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, DexCom presently has an average rating of “Buy” and a consensus price target of $95.50.

Check Out Our Latest Analysis on DXCM

Insiders Place Their Bets

In other news, EVP Jereme Sylvain sold 3,638 shares of DexCom stock in a transaction that occurred on Thursday, September 10th. The shares were sold at an average price of $83.27, for a total transaction of $302,936.26. Following the sale, the executive vice president owned 146,828 shares in the company, valued at $12,226,367.56. This trade represents a 2.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total transaction of $549,537.56. Following the transaction, the director owned 29,293 shares of the company’s stock, valued at approximately $2,461,783.72. This represents a 18.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders have sold 22,822 shares of company stock valued at $1,920,193. 0.28% of the stock is owned by company insiders.

DexCom Company Profile

(Free Report)

DexCom, Inc. develops and markets continuous glucose monitoring (CGM) systems for people with diabetes. Its wearable sensors measure glucose levels throughout the day and send readings to compatible receivers or mobile devices, helping users monitor glucose trends and support treatment decisions. The company’s products include its Dexcom G6 and G7 CGM systems, along with software and connected services for users and caregivers. DexCom also offers Stelo, an over-the-counter glucose biosensor designed for adults who do not use insulin.

Further Reading

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM – Free Report).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.